18:36 IST
BSE
Annual Report
Beryl Drugs Annual Report
Beryl Drugs Ltd has submitted its 33rd Annual Report for the financial year 2025-26, scheduled for its upcoming Annual General Meeting.
Beryl Drugs Ltd
- Share price
- ₹23.23
- Market cap
- ₹11.78 Cr
- Revenue (annual)
- ₹18.82 Cr
- Net profit (annual)
- ₹0.42 Cr
- P/E (TTM)
- 18.9×Sector 50.4×
- Promoter holding
- 27.82%+0.34% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
5 announcements
23:58 IST
BSE
Annual General Meeting
Beryl Drugs Annual General Meeting
Beryl Drugs Ltd has announced the closure of its register of members from September 23 to September 29, 2026, for its 33rd Annual General Meeting.
17:11 IST
BSE
Board Meeting Outcome
Beryl Drugs Board Meeting Outcome
Beryl Drugs Limited approved items for its 33rd Annual General Meeting and a proposal to increase material related party transaction limits.
17:16 IST
BSE
Financial Results
Beryl Drugs Q1 FY27 Results: Net Profit ₹0.2 Cr, Down 66.7% QoQ
Beryl Drugs Ltd reported revenue from operations of ₹7.3 Cr (+52.1% YoY) and net profit of ₹0.2 Cr for Q1 FY27.
- Key figure
- Net profit ₹0.2 Cr
19:05 IST
BSE
Financial Results
Beryl Drugs Q4 FY26 Results: Net Profit ₹0.6 Cr, Up 200.0% YoY
Beryl Drugs Ltd reported revenue from operations of ₹5.5 Cr (+5.8% YoY) and net profit of ₹0.6 Cr (+200.0% YoY) for Q4 FY26.
- Key figure
- Net profit ₹0.6 Cr · +200.0% YoY